Category: 3395-91-3

Computed Properties of C4H7BrO2. The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: Methyl 3-bromopropanoate, is researched, Molecular C4H7BrO2, CAS is 3395-91-3, about Iodinated Cyanine Dyes for Fast Near-Infrared-Guided Deep Tissue Synergistic Phototherapy. Author is Cao, Jie; Chi, Jinnan; Xia, Junfei; Zhang, Yanru; Han, Shangcong; Sun, Yong.

Phototheranostics, which combines deep tissue imaging and phototherapy [photodynamic therapy (PDT) and/or photothermal therapy (PTT)] via light irradiation, is a promising strategy to treat tumors. Near-IR (NIR) cyanine dyes are researched as potential phototheranostics reagents for their excellent photophys. properties. However, the low singlet oxygen generation efficiency of cyanine dyes often leads to inadequate therapeutic efficacy for tumors. Herein, we modified an indocyanine green derivative Cy7 with heavy atom iodine to form a novel NIR dye CyI to improve the reactive oxygen species (ROS) production and heat generation while, at the same time, maintain their fluorescence characteristics for in vivo noninvasive imaging. More importantly, in vitro and in vivo therapeutic results illustrated that CyI could quickly and simultaneously generate enhanced ROS and heat to induce more cancer cell apoptosis and higher inhibition rates in deep HepG2 tumors than other noniodinated NIR dyes upon NIR irradiation Besides, low toxicity of the resulted iodinated NIR dyes was confirmed by in vivo biodistribution and acute toxicity. Results indicate that this low toxic NIR dye could be an ideal phototheranostics agent for deep tumor treatments. Our study presents a novel approach to achieve the fast-synergistic PDT/PTT treatment in deep tissues.

Here is a brief introduction to this compound(3395-91-3)Computed Properties of C4H7BrO2, if you want to know about other compounds related to this compound(3395-91-3), you can read my other articles.

Reference:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 3395-91-3, is researched, Molecular C4H7BrO2, about Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies, the main research direction is pyrimidinaminopyrazole hydroxamate preparation JAK HDAC inhibitor hematol malignancy treatment; selected pyrimidinaminopyrazole compound pharmacokinetic study bioavailability antitumor efficacy.COA of Formula: C4H7BrO2.

Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concentration at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines. Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation. Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration. Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model. Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.

Here is a brief introduction to this compound(3395-91-3)COA of Formula: C4H7BrO2, if you want to know about other compounds related to this compound(3395-91-3), you can read my other articles.

Reference:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Related Products of 3395-91-3. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: Methyl 3-bromopropanoate, is researched, Molecular C4H7BrO2, CAS is 3395-91-3, about Use of Green Solvents in Metallaphotoredox Cross-Electrophile Coupling Reactions Utilizing Lipophilic Modified Dual Ir/Ni Catalyst System. Author is Delgado, Pete; Glass, Raoul J.; Geraci, Gina; Duvadie, Rohit; Majumdar, Dyuti; Robinson, Richard I.; Elmaarouf, Imran; Mikus, Malte; Tan, Kian L..

Facilitating photoredox coupling reactions in process friendly green solvents was achieved by the successful application of the dual Ir/Ni catalyst system with enhanced solubility properties. These photochem. reactions (specifically Br-Br sp2-sp3 cross electrophile coupling) are reported in a head to head comparison to the reactions using standard di-t-Bu bipyridine ligand Ir/Ni catalyst system. This presentation highlights the benefits of altering the solubility properties of the ligands used in the Ir/Ni dual catalyst.

Here is a brief introduction to this compound(3395-91-3)Related Products of 3395-91-3, if you want to know about other compounds related to this compound(3395-91-3), you can read my other articles.

Reference:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: Methyl 3-bromopropanoate, is researched, Molecular C4H7BrO2, CAS is 3395-91-3, about Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(IV) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism, the main research direction is platinum quinoloneoxoalkylcarboxylate complex preparation antitumor DNA cleavage.Safety of Methyl 3-bromopropanoate.

The design of novel platinum(IV) complexes with mitochondria injury competence, besides the DNA damage mechanism, is a promising way to develop new platinum drugs. Herein, dihydro-2-quinolone (DHQLO) as a mitocan was incorporated into the platinum(IV) system for the first time to prepare a new series of DHQLO platinum(IV) compounds Complex 1b could effectively inhibit the proliferation of tumor cells in vitro and in vivo. It accumulated at higher levels in both whole cells and DNA, and easily underwent intercellular reduction to release platinum(II) and DHQLO moieties. The released platinum(II) complex caused serious DNA damage by covalent conjunction with the DNA duplex, and remarkably increased the expression of the γ-H2AX protein. Moreover, 1b also caused serious mitochondria injury to induce mitochondrial membrane depolarization and increase ROS generation. Such actions upon DNA and mitochondria activate the p53 apoptotic pathway synergetically in tumor cells by upregulating the protein p53 and apoptotic proteins caspase9 and caspase3, which efficiently promoted the apoptotic death of tumor cells. Compound 1b with such synergic mechanism exhibited great potential in reversing cisplatin resistance and improving antitumor efficacies.

Here is a brief introduction to this compound(3395-91-3)Safety of Methyl 3-bromopropanoate, if you want to know about other compounds related to this compound(3395-91-3), you can read my other articles.

Reference:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 3395-91-3, is researched, Molecular C4H7BrO2, about Electrochemical Synthesis of 2-Bromoethyl and 2-Iodoethyl Ketones from Cyclopropanols, the main research direction is haloalkyl ketone preparation; alkyl cyclopropanol magnesium halide electrochem regioselective ring opening halogenation.Formula: C4H7BrO2.

A simple electrochem. protocol for the preparation of 2-bromoethyl- and 2-iodoethyl ketones from cyclopropanols and magnesium halides were developed. The reaction proceeded with exclusive regioselectivity and without epimerization of the α-stereocenter in the products. The synthesized diastereomerically pure 2-bromoethyl ketones underwent smooth copper and nickel-catalyzed alkylation, alkenylation, and arylations reactions.

Here is a brief introduction to this compound(3395-91-3)Formula: C4H7BrO2, if you want to know about other compounds related to this compound(3395-91-3), you can read my other articles.

Reference:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: Methyl 3-bromopropanoate( cas:3395-91-3 ) is researched.Related Products of 3395-91-3.Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie published the article 《Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies》 about this compound( cas:3395-91-3 ) in Journal of Medicinal Chemistry. Keywords: pyrimidinaminopyrazole hydroxamate preparation JAK HDAC inhibitor hematol malignancy treatment; selected pyrimidinaminopyrazole compound pharmacokinetic study bioavailability antitumor efficacy. Let’s learn more about this compound (cas:3395-91-3).

Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concentration at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines. Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation. Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration. Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model. Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.

Here is a brief introduction to this compound(3395-91-3)Related Products of 3395-91-3, if you want to know about other compounds related to this compound(3395-91-3), you can read my other articles.

Reference:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem